| abstract |
Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors and PD-1 pathway inhibitors. |